Abstract: The present invention includes a method for determining nucleic acid contributors to a sample from nucleic acids by determining one or more macrohaplotypes, comprising the steps of: obtaining or having obtained a sample; designing macrohaplotypes to obtain two or more markers selected from Short Tandem Repeat (STR), Single Nucleotide Polymorphisms (SNPs), Insertion-Deletions (Indels), or combinations thereof; generating amplicons or obtaining a sequence of amplicons from the sample from a paternal, maternal, or both chromosomes; sequencing the amplified products with LRS technologies; calling the haplotype variants of the sequence data; calculating from the one or more macrohaplotypes one or more nucleic acid contributors to the biological sample or specimen; comparing the one or more macrohaplotypes to a reference or known macrohaplotype profile from a subject suspected of contributing nucleic acids to the sample; and identifying a number of contributors to the sample.

Abstract: Provided is a canola variety designated 40056173-41 and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 40056173-41 with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 40056173-41 through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 40056173-41, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 40056173-41 are disclosed.

Abstract: Provided is a canola variety designated 20GN1632N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 20GN1632N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 20GN1632N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 20GN1632N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 20GN1632N are disclosed.

Abstract: Provided is a canola variety designated 18GM0789N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 18GM0789N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 18GM0789N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 18GM0789N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 18GM0789N are disclosed.

Abstract: Provided is a canola variety designated 19MM0047N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 19MM0047N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 19MM0047N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 19MM0047N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 19MM0047N are disclosed.

Abstract: Provided is a canola variety designated 18GM0788N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 18GM0788N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 18GM0788N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 18GM0788N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 18GM0788N are disclosed.

Abstract: Provided is a canola variety designated 21GG2040N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 21GG2040N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 21GG2040N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 21GG2040N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 21GG2040N are disclosed.

Abstract: Provided is a canola variety designated 20GU2279N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 20GU2279N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 20GU2279N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 20GU2279N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 20GU2279N are disclosed.

Abstract: Provided is a canola variety designated 4005A435-18 and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 4005A435-18 with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 4005A435-18 through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 4005A435-18, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 4005A435-18 are disclosed.

Abstract: Provided is a canola variety designated 19MM0052N and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 19MM0052N with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 19MM0052N through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 19MM0052N, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 19MM0052N are disclosed.

Abstract: Provided is a canola variety designated 4005A678-18 and seed, plants and plant parts thereof produced from a cross of inbred varieties. Methods for producing a canola variety comprise crossing canola variety 4005A678-18 with another canola plant. Methods for producing a canola plant containing in its genetic material one or more traits introgressed into 4005A678-18 through backcross conversion and/or transformation, and to the canola seed, plant and plant part produced thereby are described. Canola variety 4005A678-18, the seed, the plant produced from the seed, plant parts and variants, mutants, and minor modifications of canola variety 4005A678-18 are disclosed.

Abstract: Provided herein are compounds of Formula I, Formula II Formula III which are useful in labeling tissues in a subject (e.g., PET imaging of a subject), for treatment of cancer, and/or for preparing a medicament. Also provided are compounds containing a group that is reactive with sulfenylated proteins for treatment of cancer and/or for preparing a medicament. Methods of synthesis of the compounds and precursor compounds are also provided.

Abstract: The various embodiments of the present invention provide a system, including methods, apparatus and kits for connecting bones and/or bone portions using a multi-part bone connector with one or more rotating joints.

Abstract: The various embodiments of the present invention provide a system, including methods, apparatus and kits for connecting bones and/or bone portions using a multi-part bone connector with one or more rotating joints.

Abstract: The presently disclosed subject matter relates to the fields of pharmacology and medicine, and provides vaccine compositions and methods of use, particularly influenza compositions and methods of use to treat neonatal subjects.

Abstract: A polymeric foam article with a polymer matrix defining multiple cells therein has a polymer component with a first polymer that is a polyhedral oligomeric silsesquioxane grafted polymer that has a weight-average molecular weight of two kilograms per mole or higher and 200 kilograms per mole or lower.

Abstract: A polymeric foam article with a polymer matrix defining multiple cells therein has a polymer component with a first polymer that is a polyhedral oligomeric silsesquioxane grafted polymer that has a weight-average molecular weight of two kilograms per mole or higher and 200 kilograms per mole or lower.

Abstract: Butadiene polymers are brominated using a quaternary ammonium or quaternary phosphonium tribromide as the brominating agent. The bromination is performed in a solvent mixture than contains at least one polyhalogenated alkane and at least one monohalogenated alkane. The process proceeds easily under mild conditions and allows high conversions to be achieved easily.

Abstract: Disclosed are nitroxide modified NSAID compounds of the formula (I) or a pharmaceutically acceptable salt or enantiomer thereof: in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and n are defined herein and pharmaceutical compositions thereof. Further disclosed is a method of treating or preventing various disorders, such as inflammation, cancer, diabetes, a cardiovascular disorder, weight gain, polyps, and/or chronic pain, in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt or enantiomer of formula (I). A method of imaging the compound or pharmaceutically acceptable salt or enantiomer of formula (I) in the body of the animal is also provided.

Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.